Search This Blog

Friday, May 1, 2026

FDA OKs Arvinas' VEPPANU, first PROTAC therapy, for ESR1‑mutated ER+/HER2- advanced breast cancer

 


  • Approval of VEPPANU represents Arvinas' first approved medicine since the company's founding.
  • FDA decision came ahead of the previously assigned June 5 PDUFA date for vepdegestrant.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)